• Raised A$6.5m through institutional placement
• Completed A$18m vendor financing facility
• Progressing surgical robot validation process

CurveBeam AI Ltd (ASX: CVB) has received firm commitments from institutional and sophisticated investors for A$6.5m through the issue of approximately 72.2m new fully paid ordinary shares at a price of $0.09 per share via a single tranche placement. The new funds will be used for sales and marketing expenses, research and development costs, supply chain costs, and general working capital purposes. In conjunction with the placement, CurveBeam AI has also completed a €10m (~A$18m) Vendor Financing Facility Agreement with a specialist Swiss financing partner to help support the growth of placements of CurveBeam AI's HiRise devices, particularly in orthopaedic surgeon offices. The company is pleased to report increased engagement from the vendor of a major robotic system for the validation of the enhanced HiRise device, with constructive discussions and positive feedback received. CurveBeam AI has also entered into a confidential and non-binding term sheet with a Chinese medical device distributor/manufacturer regarding a potential 10-year exclusive distribution and manufacturing agreement for the company's products in China, Hong Kong, Macau and Taiwan, including a $10m equity investment.

The company expects to finish Q1 FY26 with cash of approximately A$2.0m, which will be further enhanced by the receipt of $6.5m (prior to costs) under the Placement. HiRise purchase orders for Q1 FY26 are currently targeted to be 4.

CurveBeam AI is at an exciting stage of its development, with a number of new growth initiatives being implemented, such as the vendor financing option, which the company is targeting to aid in the sale of the HiRise devices moving forward.